The specter of generic competition has repeatedly loomed above copyright’s iconic drug, Viagra, triggering questions about the future of similar drug investments. While initial years saw substantial profits, the patent expiration has allowed the door for less expensive substitutes, likely reducing revenue and presenting a significant danger for s